Clinical Trial Update: A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial of ARRY-371797 (PF-07265803) in symptomatic dilated cardiomyopathy due to Lamin A/C gene mutation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• ARRY-371797

Snippet

Sponsor: Pfizer | Conditions: Dilated Cardiomyopathy, Lamin A/C Gene Mutation | Phase 3 | Status: TERMINATED | Results posted: 2024-01-09